Original Research Article

Clinical profile and bacteriological etiology in cases of acute exacerbation of COPD in a tertiary care: a tertiary care study

K. A. Sahana Neelamma, Dinesh Ragav E.*

Department of General Medicine, Sri Sathyasai Medical College and Research Institute, Ammapettai, Chengalpettu District, Tamil Nadu, India

Received: 08 April 2021
Revised: 18 April 2021
Accepted: 19 April 2021

*Correspondence:
Dr. Dinesh Ragav E.,
E-mail: dr.dineshragav89@gmail.com

ABSTRACT

Background: Acute exacerbation a prominent feature of COPD, is a major entity altering the course of the disease. These exacerbations are by complex interactions between host, bacteria, viruses and environment. Many studies done earlier indicate bacteria being the major cause of these exacerbations. This study is hence done to determine the bacteriological profile, haematological profile severity and grade clinical signs and symptoms based of ‘Gold’ criteria.

Methods: A cross sectional descriptive study, done on a total of 80 cases for a period of 18 months on patients admitted to Sathya Sai medical college with acute exacerbations of chronic obstructive pulmonary disease. Cases of acute exacerbation of COPD satisfying the eligibility criteria were included in the study. Clinical and microbiological parameters were noted with special preference to sputum culture and spirometry.

Results: Bacteria was not present in 46 (57.5%) of the study population. Klebsiella pneumoniae was present in 12 cases (15.0%), pseudomonas aeruginosa in 6 (7.5%), staphylococcus aureus in 6 (7.5%), streptococcus pneumoniae in 5 (6.2%) and actinobacter in 5 (6.2%). 34 cases were sensitive to antibiotics (52.5%). Majority being sensitive to ceftriaxone, piperacillin and levofloxacillin. 43 cases belonged to ‘Gold’ criteria on spirometry. Hyper inflated lung, tubular heart was present in 39 (48.8%) cases. With normal chest X-ray findings in the rest.

Conclusions: Bacteria causing exacerbations is different in India as compared to other studies from different countries. Klebsiella pneumonia being most common organism followed by Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pneumoniae and actinobacter. AECOPD patients with bacteria showed sensitivity to ceftriaxone, piperacillin and levofloxacin. Hence, these etiology with sensitivity pattern should be kept in mind for starting a patient on empirical antibiotic therapy.

Keywords: AECOPD, COPD, Acute exacerbation of chronic obstructive pulmonary disease, Chronic obstructive pulmonary disease, Bacteriological profile, Antibiotic sensitivity

INTRODUCTION

Chronic obstructive pulmonary disease (COPD), is an obstructive disease of the airway which includes emphysema and chronic bronchitis. There is a gradually progressive airflow limitation causing reduction in lung functions. Acute exacerbations interrupts the normal course of the disease. It’s a preventable non-reversible airway disease. COPD today is the third major cause of death all around the world. Exacerbations is associated with increased mortality and morbidity, reducing the quality of life, increased health care expenditures.

Exacerbations of COPD during the course of the disease is defined as sustained worsening of the patient’s condition from stable state, which is acute causing change of
prescription and requiring hospitalisation. These are due to complex involvement of host, bacteria and environment.

Tobacco smoking is a major risk factor for COPD. Several other studies suggest bacterial and viral infections as the major cause of exacerbation. Major studies suggest haemophilus influenza, streptococcus pneumoniae, moraxella and pseudomonas as the major cause involved in exacerbations.

Several other viruses and bacteria are also involved in causing exacerbations. Emergent pathogens causing the disease are beta lactamase and metallo beta lactamase.

The studies done in India regarding the cause of exacerbation is less. Hence, this study is undertaken to put forth the profile, antibiogram, the haematological profile and severity of clinical findings based bacteriological on ‘Gold’ criteria.

METHODS

This is a cross sectional descriptive study done among a total of 80 cases both men and women. Patients included were all above 40 years with acute exacerbation of COPD admitted in Shri Sathya Sai medical college, Ammapettai, Tamil Nadu. Study was conducted for a period of 18 months from March 2019 to September 2020. Cases of acute exacerbation were those with increase in sputum quantity, needing hospital admission or a new prescription.

Patients included in the study were known cases of COPD over the age of 40 years who may or may not be a smoker, having features of sudden increase of cough and shortness of breath, change in the volume of sputum or its purulence, patient becoming febrile with neutrophilia, spirometry findings shows increased reduction of FEV1 and FEV1/FVC ratio. Increase in the stage of ‘Gold’ criteria.

Patients who had no history of COPD in the past, patients who is a case of COPD, now with exacerbation and already on antibiotics, patients with bronchiectasis findings on chest X-ray PA view, patients with tuberculosis of lung on ATT, patients with restrictive pattern of lung disease and patient with lung cancers were excluded from the study. The minimum calculated sample size from the previous study with a prevalence of 47.22% is 80.

Procedure

Ethical committee approval was taken from the institution before the starting the study. Sampling was eventually followed. After establishing a good rapport with the study subjects, the purpose, procedure objectives, benefits, risks and confidentiality of the procedure was explained to the study subjects in their local dialect. An informed consent from the study subject was taken before the interview.

Data was collected from eligible patients such as the age, sex, body mass index were noted. Smokers were identified. Past medical history was obtained. Sputum examination, chest X-ray and spirometry was done. Sputum samples were sent for sputum culture, antibiotic sensitivity testing. Spirometry assessed FEV1 and FEV1/FVC ratio. Total leucocyte count and differential count was checked using 5 ml of venous blood from the patient taken under septic precautions.

Statistical analysis

Data collected was put up in an excel sheet, SPSS software 16th version was used for the analysis. P-value below 0.05 was considered significant.

RESULTS

In a total of 80 patients, all had cough, shortness of breath and chest pain. 53 cases had fever, 13 cases had chest pain (Table 1), 38 patients were smokers with 10 minimum pack years and maximum of 50 pack years. Among the comorbidities, 13 patients had diabetes mellitus, 16 had coronary artery disease and 1 patient had epilepsy.

Table 1: General examination findings of the study population.

| Clinical finding    | Frequency | Percentage |
|---------------------|-----------|------------|
| Cough               | 80        | 100        |
| Expectoration       | 80        | 100        |
| Breathlessness      | 80        | 100        |
| Fever               | 53        | 66.2       |
| Chest pain          | 13        | 16.2       |

In bacteriological profile of study population (Table 2), No bacteria was present in 46 cases. Among the cases with positive bacteriology klebsiella pneumoniae was present in 6 cases, staphylococcus aureus was present in 6 cases, streptococcus pneumoniae was present in 5 and actinobacter was present in 5.

Table 2: Bacteriological profile of the study population.

| Infection               | Frequency | Percent |
|-------------------------|-----------|---------|
| Absent                  | 46        | 57.5    |
| Klebsiella pneumoniae   | 12        | 15.0    |
| Pseudomonas aeruginosa  | 6         | 7.5     |
| Staphylococcus aureus   | 6         | 7.5     |
| Streptococcus pneumoniae| 5         | 6.2     |
| Actinobacter            | 5         | 6.2     |
| Total                   | 80        | 100.0   |

In sensitivity pattern of the study population (Table 3), Antibiotic sensitivity is present in 34 (52.5%) of the study population. Antibiotic sensitivity of the study population is represented in the following table and bar chart, (as the same patient shows sensitivity to multiple drugs, total percentages will exceed 100%).
Table 3: Antibiotic Sensitivity of the study population.

| Antibiotic sensitivity                  | Frequency | Percent |
|----------------------------------------|-----------|---------|
| Ceftriaxone                            | 29        | 36.2    |
| Cefoperazone sulbactum                 | 23        | 28.8    |
| Piperacillin tazobactum                | 29        | 36.2    |
| Gentamycin                             | 25        | 31.2    |
| Levofloxacin                           | 30        | 37.5    |
| Amoxicillin clavulanic acid            | 21        | 26.2    |
| Amikacin                               | 12        | 15      |
| Imipenem                               | 24        | 30      |
| Vancomycin                             | 5         | 6.2     |
| Linezolid                              | 5         | 6.2     |
| Clindamycin                            | 3         | 3.8     |
| Cotrimoxazole                          | 1         | 1.2     |

In spirometry findings of the study population (Table 4), Majority of the study population 43 (53.8%) were belonging to ‘Gold’ criteria 2. This is represented in the following table. Chest X-ray findings of study populations showed 49% hyperinflated lungs and 51% normal lungs.

Table 4: Spirometry findings of the study population.

| Gold criteria | Frequency | Percent |
|---------------|-----------|---------|
| 1             | 11        | 13.8    |
| 2             | 43        | 53.8    |
| 3             | 20        | 25.0    |
| 4             | 6         | 7.5     |
| Total         | 80        | 100.0   |

Table 5: Cross tabulation between presence of microorganism and spirometry and ‘Gold’ criteria.

| Micro-organism | Total Count | P-value  |
|----------------|-------------|----------|
| Spirometry     |             |          |
| 1              |             |          |
| Count          | 8           | 34       |
| % within spiro | 72.7        | 27.3     |
| 2              |             |          |
| Count          | 23          | 20       |
| % within spiro | 53.5        | 46.5     |
| 3              |             |          |
| Count          | 10          | 10       |
| % within spiro | 100.0       |          |
| 4              |             |          |
| Count          | 5           | 1        |
| % within spiro | 83.3        | 16.7     |
| Total          | 46          | 34       |
| % within spiro | 57.5%       | 42.5     |

DISCUSSION

COPD exacerbations are more common during winter when the respiratory viral infections are more prevalent in the environment. The objective of this study was to analyze the bacteriological profile by sputum culture, to do spirometry and to assess severity along with antibiotic sensitivity pattern in cases of acute exacerbation of COPD.

Anand Ambali et al, did a study on total of 66 cases on cases of acute exacerbation of COPD, in Karnataka. This study indicated that streptococcus pneumoniae was the common organism with maximum sensitivity to cefoperazone.8 This study mainly included older patients and showed a mortality rate of 1.5%. This was supported by many other studies, which said that older patents had a higher mortality rate. In this study participants, all had cough, sputum and breathlessness. Fever was present in 53 cases and chest pain in 13. This symptomatology was similar to studies done by Arora N et al.9

In the study done above, 38 patients were smokers. The mean pack years being 24.12 and median was 23.5. The minimum pack years being 10 and maximum being 50.
The severity of COPD was influenced by colonization of bacteria and viruses and smoking.\textsuperscript{10}

Gauri Kulkarni et al. did a study on 45 patients in Nashik on cases of acute exacerbation of COPD quoted that AECOPD is much more in males over 50 years of age with smoking habits.\textsuperscript{11}

Many previously published studies done outside India suggests bacteria and virus as the major cause of AECOPD. A very minority of studies suggest environment factors as the cause. Study results are similar to the ones done in India but very few in number.\textsuperscript{12,13}

Chawla K et al, hospital-based study done in Karnataka on AECOPD patients, quoted bacteriology as the cause in 50 percent of cases. Pseudomonas aeruginosa as the most common cause followed by klebsiella and haemophilus.\textsuperscript{14} Anand Patel et al, quoted streptococcus pneumoniae as the most common cause.\textsuperscript{15}

Emergence of antibiotic resistance is increasing on day to day basis.\textsuperscript{16} Alaa Hassan et al did a study on 156 patients and quoted that the commonest bacterial resistance was towards penicillins and cephalosporins followed by fluoroquinolones. Also, more severe disease is associated with increased resistance.\textsuperscript{17} Anand Patel et al, indicated piperacilline and tazobactum as very effective antibiotic for the most common organisms.\textsuperscript{18} Gauri Kulkarni et al, quoted ciprofloxacin with amikacin as the best choice for empirical therapy. This study had 39 cases with hyperinflated lung and tubular heart suggesting the clinical severity of cases in acute exacerbation of COPD.\textsuperscript{17} Also, mortality rates were correlated with decreased lung parameters. Study done by Parvaiz Koul et al, suggested the various factors associated with increased mortality.\textsuperscript{18}

This study is a hospital-based study carried out in tertiary care setting. Hence, it cannot be applied to the rural areas with primary health care settings. Follow up of sputum cultures was not performed, hence the resistance pattern for further use could not be interpreted. Bronchoscopy was not the method used to collect sample which is a better method to be done in order to study the microbiology.

Limitation of this study was, if a greater number of cases had been studied and more time had been there, the study would have had a broader spectrum of pathogens involved. This study was a hospital-based study carried out in tertiary care setting. Hence, it cannot be applied to the rural areas with primary health care settings.

\textbf{CONCLUSION}

All the patients in the study had cough, shortness of breath and expectoration indicated the clinical severity of cases of acute exacerbation of COPD. Fever was present in 53 cases and chest pain in 13 cases, 38 cases in the study were smokers which suggests smoking as an important factor in the episodes of exacerbations.

Bacteria was not present in 46 cases. Among the cases with positive bacteriology klebsiella pneumoniae was present in 12, pseudomonas aeruginosa was present in 6, staphylococcus aureus was present in 5 and actinobacter in 5 cases. Majority of the organisms were sensitive to ceftriaxone, piperacilline and levofloxacin. Hence, these drugs can be chosen as empirical antibiotics in the early management of AECOPD cases.

By spirometry majority of the cases belonged to GOLD criteria 2, which indicates the severity in the reduction of a lung functions and hence the quality of life.

\textbf{ACKNOWLEDGEMENTS}

Authors would like to thank our nursing staff of medical ICU, our sincere thanks to statistician. We are also grateful to all patients included in our study.

\textbf{Funding: No funding sources}

\textbf{Conflict of interest: None declared}

\textbf{Ethical approval: The study was approved by the Institutional Ethics Committee}

\textbf{REFERENCES}

1. Petty TL, Weinmann GG. Building a national strategy for the prevention and management of and research in chronic obstructive pulmonary disease. National Heart, Lung, and Blood Institute Workshop Summary. Bethesda, Maryland, August 29-31, 1995. JAMA. 1997;277(3):246-53.
2. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J. 2003;22(4):672-88.
3. May SM, Li JT. Burden of chronic obstructive pulmonary disease: healthcare costs and beyond. Allergy Asthma Proc. 2015;36(1):4-10.
4. Sapey E, Stockley RA. COPD exacerbations. 2: aetiology. Thorax. 2006;61(3):250-8.
5. Viegi G, Pistelli F, Sherrill DL, Maio S, Baldacci S, Carrozzii L. Definition, epidemiology and natural history of COPD. Eur Respir J. 2007;30(5):993-1013.
6. Qureshi H, Sharafkhanneh A, Hanania NA. Chronic obstructive pulmonary disease exacerbations: latest evidence and clinical implications. Ther Adv Chronic Dis. 2014;5(5):212-27.
7. Kuwal A, Joshi V, Dutt N, Singh S, Agarwal KC, Purohit G. A Prospective Study of Bacteriological Etiology in Hospitalized Acute Exacerbation of COPD Patients: Relationship with Lung Function and Respiratory Failure. Turk Thorac J. 2018;19(1):19-27.
8. Wang YJ, Jin XJ. Evidence-based medicine in China. Chronic Dis Transl Med. 2019;5(1):1-5.
9. Arora N, Daga MK, Mahajan R, Prakash SK, Gupta N. Microbial pattern of acute infective exacerbation of chronic obstructive airway disease in a hospital-
based study. Indian J Chest Dis Allied Sci. 2001;43(3):157-62.
10. Hassan A, Mohamed S, Mohamed M, Mokhtar M. Acute exacerbations of chronic obstructive pulmonary disease: etiological bacterial pathogens and antibiotic resistance in Upper Egypt. Egypt J Bronchol. 2016;10(3):283.
11. Kulkarni G, Chaudhary D, Bhoyar A, Dugad S. Bacteriological Profile in Sputum and their Antibiogram among the Patients of Acute Exacerbation of COPD. MVP J Med Sci. 2017;4(2):113-7.
12. Iyer PG, Murphy TF. Chronic obstructive pulmonary disease: role of bacteria and updated guide to antibacterial selection in the older patient. Drugs Aging. 2009;26(12):985-95.
13. Erkan L, Uzun O, Findik S, Katar D, Sanic A, Atici AG. Role of bacteria in acute exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2008;3(3):463-7.
14. Chawla K, Mukhopadhay C, Majumdar M, Bairy I. Bacteriological profile and their antibiogram from cases of acute exacerbations of chronic obstructive pulmonary disease: A hospital-based study. J Clin Diagnostic Res. 2008;2(1):612-6.
15. Dimopoulos G, Tsiodras S, Lerikou M, Chranioti A, Perros E, Anagnostopoulou U, et al. Viral Profile of COPD Exacerbations According to Patients. Open Respir Med J. 2015;9:1-8.
16. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268-81.
17. Kulkarni G, Chaudhary D, Bhoyar A, Dugad S. Bacteriological Profile in Sputum and their Antibiogram among the Patients of Acute Exacerbation of COPD. MVP J Med Sci. 2017;4(2):113-7.
18. Koul PA, Dar HA, Jan RA, Shah S, Khan UH. Two-year mortality in survivors of acute exacerbations of chronic obstructive pulmonary disease: A North Indian study. Lung India. 2017;34(6):511-6.

Cite this article as: Neelamma KAS, Dinesh RE. Clinical profile and bacteriological etiology in cases of acute exacerbation of COPD in a tertiary care: a tertiary care study. Int J Adv Med 2021;8:696-700.